General description
INN
Amikacin
ATC codes
Medicine type
Chemical agent
Antibiotic groups
EML status history
First added in 1999
(TRS
895)
for
Multi-drug resistant Mycobacterium tuberculosis
Added in 2017
(TRS
1006)
for
Sepsis without septic shock
Added in 2017
(TRS
1006)
for
Neutropenia
Added in 2017
(TRS
1006)
for
Acute pyelonephritis
Added in 2017
(TRS
1006)
for
Inflammatory and other diseases of prostate
Changed in 2021
(TRS
1035)
for
Infectious blepharitis
Changed in 2021
(TRS
1035)
for
Other specified conjunctivitis
Therapeutic equivalent for
Wikipedia
DrugBank
Recommendations
Section
Access group antibiotics
- Parenteral > General injections > unspecified: 250 mg per mL in 2 mL vial (as sulfate); 50 mg per mL in 2 mL vial (as sulfate)
- Parenteral > General injections > unspecified: 250 mg per mL in 2 mL vial (as sulfate)
Indications
First choice
Neutropenia (high-risk) co-prescribed with cefotaxime Acute pyelonephritis (severe) co-prescribed with cefotaxime Inflammatory and other diseases of prostate (severe) co-prescribed with ceftriaxone Acute pyelonephritis (severe) co-prescribed with ceftriaxone Inflammatory and other diseases of prostate (severe)Second choice
co-prescribed with cloxacillin Sepsis without septic shock
Section
Antituberculosis medicines
- Parenteral > General injections > unspecified: 250 mg per mL in 2 mL vial (as sulfate)
Indications